arterivirus
famili
anim
virus
includ
prototyp
equin
arter
viru
eav
porcin
reproduct
respiratori
syndrom
viru
prrsv
wherea
outbreak
equin
viral
arter
eva
occasion
report
infect
prrsv
pose
major
threat
swinefarm
industri
worldwid
especi
emerg
highli
virul
strain
prrsv
china
sinc
major
concern
zhou
yang
although
current
vaccinebas
control
strategi
eav
consid
adequ
concern
regard
efficaci
ie
limit
cross
protect
safeti
ie
shed
vaccin
viru
provid
room
improv
balasuriya
et
al
mccollum
et
al
contrast
wherea
current
avail
vaccin
prrsv
gener
provid
protect
clinic
diseas
consist
prevent
replic
field
strain
shed
infecti
viru
especi
limit
protect
heterolog
field
strain
major
issu
kimman
et
al
design
novel
prrsv
vaccin
provid
improv
protect
homolog
heterolog
field
strain
therefor
signific
import
suggest
immuneevas
capabl
prrsv
play
import
role
reduc
vaccin
efficaci
kimman
et
al
wang
et
al
one
arteriviru
protein
domain
suggest
involv
downregul
innat
immun
respons
papainlik
proteas
friasstah
et
al
sun
et
al
van
kasteren
et
al
function
deubiquitinas
deubiquitinas
interferon
vaccin
eav
prrsv
arteriviru
arterivirus
famili
positivestrand
rna
virus
includ
prototyp
equin
arter
viru
eav
porcin
reproduct
respiratori
syndrom
viru
prrsv
although
sever
vaccin
virus
commerci
avail
room
improv
especi
case
prrsv
abil
arterivirus
counteract
immun
respons
thought
decreas
efficaci
current
modifi
live
viru
vaccin
recent
shown
deubiquitinas
dub
activ
eav
papainlik
proteas
import
inhibit
innat
immun
activ
infect
vaccin
viru
lack
dub
activ
may
therefor
immunogen
provid
improv
protect
subsequ
challeng
dubcompet
counterpart
test
hypothesi
twenti
shetland
mare
randomli
assign
one
three
group
two
group
vaccin
either
dubposit
n
dubneg
n
recombin
eav
third
group
n
vaccin
hors
subsequ
challeng
virul
strain
eav
vaccin
virus
prove
replic
compet
vivo
addit
dubneg
viru
provid
similar
degre
protect
clinic
diseas
dubposit
parent
counterpart
owe
alreadi
high
level
protect
provid
parent
viru
possibl
improv
due
inactiv
dub
activ
could
detect
experiment
condit
taken
togeth
data
obtain
studi
warrant
vivo
investig
potenti
use
dubmut
virus
improv
arteriviru
vaccin
elsevi
bv
right
reserv
dub
play
essenti
role
f
f
autoproteolyt
matur
viral
replicas
polyprotein
importantli
recent
abl
show
dub
activ
eav
inhibit
innat
immun
respons
infect
cell
via
structurebas
design
viabl
mutant
viru
lack
activ
van
kasteren
et
al
aim
current
studi
determin
vivo
whether
dubneg
viru
provid
better
protect
subsequ
challeng
infect
parent
dubcompet
counterpart
sinc
date
separ
dub
polyprotein
process
function
arteriviru
success
eav
use
viru
present
anim
studi
cell
cultur
glasgow
minimum
essenti
medium
lonza
supplement
foetal
bovin
serum
fb
tryptos
phosphat
broth
mm
hepe
ph
primari
equin
lung
fibroblast
elf
cultur
minimum
essenti
medium
lonza
supplement
fb
grown
collagenco
plastic
maximum
passag
vero
cell
cultur
proprietari
cell
cultur
medium
msd
anim
health
supplement
fb
cultur
media
contain
uml
penicillin
mgml
streptomycin
neomycin
clone
product
dubcompet
previou
public
refer
wildtyp
dubneg
amino
acid
number
base
polyprotein
virus
strain
bucyru
use
vaccin
describ
previous
van
kasteren
et
al
virus
thoroughli
character
cell
f
f
cultur
experi
reveal
differ
replic
kinet
yet
strongli
decreas
dub
activ
enhanc
induct
interferon
beta
mrna
express
hallmark
innat
immun
activ
mutant
viru
compar
parent
counterpart
van
kasteren
et
al
viral
titr
determin
standard
plaqu
assay
elf
experiment
challeng
use
virul
kentucki
strain
eav
previous
describ
zhang
et
al
confirm
use
correct
viru
vaccin
presenc
absenc
mutat
establish
vaccin
vaccin
viral
rna
isol
produc
viru
stock
use
qiaamp
viral
rna
mini
kit
qiagen
convert
cdna
use
revertaid
h
minu
revers
transcriptas
rt
fermenta
random
hexam
primer
region
subsequ
pcr
amplifi
use
pfu
dna
polymeras
fermenta
sequenc
vaccin
viral
rna
present
blood
four
hors
vaccin
group
day
post
vaccin
subject
sequenc
done
essenti
describ
except
rt
reaction
whole
blood
total
rna
see
perform
use
primer
recogn
eav
genom
thu
specif
convert
limit
amount
viral
rna
present
sampl
cdna
primer
sequenc
avail
upon
request
experi
perform
accord
european
commun
guidelin
nation
law
anim
experi
design
experi
approv
msd
anim
health
committe
ethic
anim
experi
dierexperimentencommissi
requir
nation
legisl
includ
msd
anim
health
employe
independ
member
prior
start
trial
permit
number
exp
effort
made
minim
anim
discomfort
twenti
femal
shetland
hors
equu
feru
caballu
averag
age
ae
year
test
neg
eavneutr
antibodi
antibodi
titr
determin
describ
previous
zhang
et
al
start
experi
randomli
assign
one
three
treatment
group
oneweek
acclimat
period
hors
group
n
group
n
receiv
intramuscular
cervic
muscl
vaccin
ml
phosphatebuff
salin
contain
plaqueform
unit
pfu
parent
dubneg
eav
f
f
respect
hors
group
n
vaccin
includ
studi
one
week
challeng
day
post
vaccin
dpv
hors
challeng
intranas
inocul
pfu
eav
total
volum
ml
phosphatebuff
salin
given
fact
virus
use
vaccin
qualifi
genet
modifi
organ
gmo
vaccin
hors
kept
contain
entir
experi
hors
hous
group
group
hors
kept
separ
group
hors
prevent
crosscontamin
hors
group
divid
among
two
stabl
upon
inclus
without
direct
contact
group
hors
water
provid
ad
libitum
standard
feed
procedur
appli
gener
health
statu
anim
check
veterinarian
vaccin
well
challeng
daili
anim
caretak
entir
cours
experi
addit
clinic
sign
record
daili
day
post
challeng
dpc
score
accord
tabl
rectal
temperatur
taken
daili
dpv
daili
dpc
blood
sampl
serum
total
rna
isol
taken
everi
day
dpv
everi
day
dpc
anim
euthan
accord
standard
procedur
dpv
dpc
schemat
overview
experiment
setup
see
fig
blood
serum
neutral
antibodi
analysi
collect
ml
vacuett
serum
clot
activ
tube
greiner
bioon
incub
least
h
room
temperatur
allow
clot
serum
sampl
subsequ
collect
centrifug
plate
subsequ
incub
day
well
score
posit
neg
cytopath
effect
cpe
visual
inspect
eav
neutral
antibodi
titr
final
determin
reciproc
valu
highest
serum
dilut
cpe
observ
total
rna
isol
whole
blood
collect
tempu
blood
rna
tube
greiner
bioon
use
magmax
stabil
blood
tube
rna
isol
kit
life
technolog
accord
manufactur
instruct
isol
rna
convert
cdna
use
revertaid
h
minu
revers
transcriptas
fermenta
oligo
dt
primer
sampl
subsequ
analyz
quantit
reversetranscriptas
qrt
pcr
touch
realtim
pcr
detect
system
biorad
use
itaq
sybr
green
supermix
biorad
primer
target
mrna
encod
equin
bactin
eav
rna
design
use
rozen
skaletski
eavspecif
primer
set
amplifi
cdna
deriv
genom
subgenom
viral
mrna
forward
primer
includ
one
mismatch
realtim
pcr
program
perform
triplic
start
min
follow
cycl
run
includ
standard
dilut
seri
follow
meltingcurv
analysi
confirm
ident
reaction
product
assess
whether
vaccin
viru
lack
dub
activ
would
provid
better
protect
heterolog
challeng
dubposit
parent
counterpart
perform
vaccinationchalleng
trial
hors
twenti
femal
shetland
hors
randomli
assign
one
three
group
anim
two
group
subsequ
vaccin
intramuscularli
cell
cultureadapt
dubcompet
group
n
dubneg
group
n
eav
hors
group
n
vaccin
serv
challeng
control
hors
intranas
challeng
f
f
virul
eav
dpv
schemat
represent
experiment
setup
includ
time
vaccin
challeng
sampl
depict
fig
ident
viru
use
vaccin
confirm
sequenc
viral
rna
isol
whole
blood
dpv
subset
four
hors
per
group
group
data
shown
upon
vaccin
anim
group
dubcompet
dubneg
viru
respect
develop
compar
level
mild
fever
reach
averag
maximum
dpv
subsid
approxim
dpv
group
fig
upon
challeng
nonvaccin
anim
group
develop
fever
reach
higher
level
averag
maximum
last
approxim
two
day
longer
mild
temperatur
increas
observ
vaccin
neutral
antibodi
could
detect
group
dpv
onward
differ
titr
observ
two
group
fig
titr
remain
stabl
cours
experi
show
increas
upon
challeng
unvaccin
control
neutral
antibodi
titr
could
detect
day
post
challeng
dpc
reach
similar
titr
observ
vaccin
dpc
clinic
sign
includ
exampl
fever
nasal
secret
loss
appetit
record
daili
anim
overal
clinic
sign
score
subsequ
determin
anim
score
clinic
sign
accord
tabl
exampl
hors
reduc
appetit
day
mucopurul
eye
discharg
temperatur
day
abnorm
day
overal
clinic
sign
score
result
averag
score
per
anim
per
day
group
group
differ
significantli
two
group
student
ttest
p
tabl
hors
group
reach
averag
score
per
anim
per
day
consist
fact
anim
vaccin
thu
vaccin
either
viru
provid
similar
high
degre
protect
clinic
diseas
assess
viral
replic
dpv
perform
realtim
qrtpcr
analysi
total
rna
isol
whole
blood
seen
fig
vaccin
hors
show
viral
replic
averag
peak
dpv
f
g
f
g
fig
schemat
represent
anim
trial
twenti
femal
shetland
hors
randomli
assign
one
three
group
start
experi
hors
group
n
vaccin
dubcompet
dubneg
eav
f
f
respect
hors
group
n
vaccin
dpv
hors
challeng
moder
virul
eav
experi
end
dpv
blood
sampl
serum
total
rna
isol
taken
indic
day
lower
arrow
group
wherea
viral
rna
could
detect
multipl
day
group
hors
dubcompet
vaccin
four
group
hors
dubneg
vaccin
viral
rna
could
detect
singl
day
ie
dpv
addit
compar
averag
amount
viral
rna
group
day
post
vaccin
consist
lower
group
compar
group
howev
differ
statist
signific
dpv
student
ttest
p
upon
challeng
f
f
virul
eav
strain
nonvaccin
control
hors
group
show
viru
replic
amount
viral
rna
reach
level
compar
produc
vaccin
virus
fig
contrast
amount
challeng
viru
rna
remain
detect
limit
assay
vaccin
hors
group
result
consist
observ
appear
neutral
antibodi
vaccin
hors
low
clinic
sign
score
vaccin
group
challeng
final
assess
induct
innat
immun
respons
parent
dubneg
viru
dpv
mean
realtim
qrtpcr
rna
extract
whole
blood
sinc
unabl
detect
mrna
encod
type
interferon
hallmark
innat
immun
activ
instead
focuss
two
highli
express
interferonstimul
gene
encod
respect
gene
show
approxim
increas
express
dpv
significantli
differ
anim
group
fig
c
dpv
express
mrna
significantli
lower
anim
vaccin
dubneg
viru
group
vaccin
parent
viru
group
student
ttest
p
f
g
f
g
might
explain
slight
decreas
replic
effici
former
viru
previous
shown
mutant
eav
lack
dub
activ
induc
potent
innat
immun
respons
dubcompet
parent
viru
upon
infect
cell
cultur
van
kasteren
et
al
hypothes
featur
might
includ
improv
arteriviru
vaccin
order
assess
whether
dubneg
vaccin
viru
provid
better
protect
dubcompet
counterpart
challeng
virul
eav
strain
perform
vaccinationchalleng
trial
hors
data
obtain
studi
show
contrast
previous
seen
cell
f
f
cultur
experi
van
kasteren
et
al
mutant
viru
appear
replic
slightli
less
effici
parent
viru
vivo
fig
even
though
dubneg
viru
clearli
replic
compet
find
suggest
role
dub
activ
support
replic
vivo
eg
inhibit
innat
immun
respons
addit
despit
slight
decreas
replic
effici
level
protect
clinic
diseas
tabl
antibodi
respons
fig
innat
immun
respons
assess
base
express
two
interferonstimul
gene
fig
c
induc
dubneg
viru
compar
induc
parent
viru
surprisingli
observ
increas
eavneutr
antibodi
titr
upon
challeng
infect
vaccin
anim
fig
possibl
explan
find
viru
dose
use
challeng
low
result
effici
clearanc
activ
antibodi
respons
taken
togeth
present
studi
could
use
substanti
refut
hypothesi
dubneg
viru
provid
better
protect
challeng
dubposit
counterpart
main
reason
seem
fact
parent
viru
alreadi
provid
high
degre
protect
turn
could
detect
improv
use
experiment
setup
hindsight
one
solut
might
perform
sever
challeng
exampl
use
higher
viru
dose
inocul
heterolog
andor
virul
strain
prrsv
vaccin
gener
less
efficaci
eav
vaccin
anoth
option
would
perform
similar
trial
prrsv
vaccin
pig
first
requir
design
viabl
prrsv
dubneg
mutant
contrast
previous
found
cell
culturebas
assay
van
kasteren
et
al
detect
increas
activ
innat
immun
dubneg
viru
compar
parent
viru
vivo
howev
need
note
thu
far
assess
express
two
interferonstimul
gene
wherea
mani
exist
therefor
remain
possibl
differ
exist
express
interferonstimul
gene
similarli
induct
interferonstimul
gene
one
sever
consequ
activ
innat
immun
signal
therefor
remain
possibl
dubneg
vaccin
viru
differ
parent
viru
respect
pertain
immun
exampl
activ
cellmedi
adapt
immun
also
dub
activ
like
constitut
one
sever
innat
immun
evas
strategi
employ
arterivirus
exampl
nonstructur
protein
eav
recent
shown
inhibit
induct
interferon
beta
luciferas
report
assay
go
et
al
prrsv
main
proteas
recent
shown
cleav
innat
immun
signal
factor
nemo
huang
et
al
also
f
g
f
g
fig
quantit
rtpcr
analysi
viral
rna
cellular
mrna
encod
viral
replic
dpv
group
dpc
group
assess
realtim
qrtpcr
analysi
total
rna
isol
whole
blood
use
eavspecif
primer
white
black
grey
circl
repres
anim
group
respect
horizont
bar
repres
mean
anim
day
dot
line
repres
limit
detect
activ
innat
immun
respons
assess
realtim
qrtpcr
total
rna
isol
whole
blood
use
primer
specif
b
c
mrna
valu
obtain
mrna
level
normal
amount
bactin
mrna
dot
line
repres
averag
baselin
level
error
bar
repres
standard
deviat
asterisk
indic
statist
signific
student
ttest
p
abbrevi
au
arbitrari
unit
dub
deubiquitinasecompet
vaccin
viru
deubiquitinaseneg
vaccin
viru
han
et
al
kim
et
al
song
et
al
beura
et
al
chen
et
al
patel
et
al
wang
et
al
nucleocapsid
protein
sagong
lee
propos
counteract
innat
immun
activ
taken
togeth
dub
activ
appear
constitut
part
total
repertoir
arteriviru
innat
immun
evas
strategi
reason
contribut
inhibit
innat
immun
perhap
readili
detect
vivo
experiment
setup
use
exampl
detect
promin
consequ
inactiv
may
depend
detail
anim
studi
includ
specif
properti
virus
hors
use
nevertheless
appar
limit
neg
effect
viral
replic
dubmut
open
possibl
combin
mutat
multipl
domain
involv
immun
evas
therebi
potenti
synergist
increas
overal
immunogen
viru
notabl
arterivirus
group
virus
shown
harbour
dub
activ
exampl
coronavirus
includ
sarsand
merscov
encod
papainlik
proteas
display
dub
activ
review
see
mielech
et
al
otu
proteas
nairovirus
also
found
possess
dub
activ
friasstah
et
al
like
arteriviru
viral
dub
implic
innat
immun
evas
friasstah
et
al
mielech
et
al
therefor
potenti
target
design
novel
vaccin
interestingli
recent
abl
show
dub
polyprotein
process
function
papainlik
proteas
encod
merscov
also
separ
target
mutagenesi
baileyelkin
et
al
taken
togeth
data
obtain
studi
definit
warrant
vivo
examin
consequ
knock
arteriviru
dub
activ
well
immuneevas
activ
improv
vaccin
efficaci
data
obtain
studi
could
subsequ
also
use
preliminari
proof
principl
design
novel
vaccin
virus
includ
coronaand
nairovirus
mk
ej
pbk
file
provision
patent
applic
relat
aspect
work
